prediction

You have access
Review of the Role of Radiomics in Tumour Risk Classification and Prognosis of Cancer
YEO LI WEN and MICHELLE LEECH

Anticancer Research July 2020, 40 (7) 3605-3618; DOI: https://doi.org/10.21873/anticanres.14350
You have access
Development of Normal Tissue Complication Probability Model for Trismus in Head and Neck Cancer Patients Treated With Radiotherapy: The Role of Dosimetric and Clinical Factors
MASAHIRO MORIMOTO, HENK P. BIJL, ARJEN VAN DER SCHAAF, CHENG-JIAN XU, ROEL J.H.M. STEENBAKKERS, OLGA CHOUVALOVA, YASUO YOSHIOKA, TERUKI TESHIMA and JOHANNES A. LANGENDIJK

Anticancer Research December 2019, 39 (12) 6787-6798; DOI: https://doi.org/10.21873/anticanres.13894
You have access
Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response
JULIA KOVACOVA, JAROSLAV JURACEK, ALEXANDR POPRACH, TOMAS BUCHLER, JINDRICH KOPECKY, ONDREJ FIALA, MAREK SVOBODA and ONDREJ SLABY

Anticancer Research May 2018, 38 (5) 2961-2965;
You have access
Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer
DIRK RADES, LIESA DZIGGEL, THEO VENINGA, AMIRA BAJROVIC and STEVEN E. SCHILD

Anticancer Research September 2016, 36 (9) 4817-4819;
You have access
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, ONDREJ TOPOLCAN, JAROSLAV RACEK, MARTIN SVATON, RADEK KUCERA, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RENATA CHLOUPKOVA, ALEXANDR POPRACH and TOMAS BUCHLER

Anticancer Research May 2016, 36 (5) 2459-2465;
You have access
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma
IVAN TRÁVNÍČEK, JINDŘICH BRANŽOVSKÝ, KRISTÝNA KALUSOVÁ, ONDŘEJ HES, LUBOŠ HOLUBEC, KEVIN BAULETH PELE, TOMÁŠ ÜRGE and MILAN HORA

Anticancer Research October 2015, 35 (10) 5661-5666;
You have access
Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin
KEIGO KOMINE, MASAHIRO INOUE, KAZUNORI OTSUKA, KOJI FUKUDA, HIROSHI NANJO and HIROYUKI SHIBATA

Anticancer Research June 2014, 34 (6) 3165-3168;
You have access
Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, LUCIE BENESOVA, MAREK MINARIK, ZBYNEK BORTLICEK and ONDREJ TOPOLCAN

Anticancer Research June 2014, 34 (6) 3205-3210;
You have access
Progression-free Survival Is Accurately Predicted in Patients Treated with Chemotherapy for Epithelial Ovarian Cancer by the Histoculture Drug Response Assay in a Prospective Correlative Clinical Trial at a Single Institution
PHILL-SEUNG JUNG, DAE-YEON KIM, MOON-BO KIM, SHIN-WHA LEE, JONG-HYEOK KIM, YONG-MAN KIM, YOUNG-TAK KIM, ROBERT M. HOFFMAN and JOO-HYUN NAM

Anticancer Research March 2013, 33 (3) 1029-1034;

Main menu

User menu

Search

prediction